FDA OK's Vanda’s Hetlioz for sleep disorder in blind

Shares of Vanda Pharmaceuticals gained $2.53, or about 20%, on 31 January after the FDA approved the company’s drug Hetlioz (tasimelteon) as circadian regulator to treat non-24-Hour (non-24), a rare sleep-wake disorder, in patients with total blindness.